NCT06924463

Brief Summary

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 13, 2025

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

April 4, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 11, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
Last Updated

April 11, 2025

Status Verified

April 1, 2025

Enrollment Period

10 months

First QC Date

April 4, 2025

Last Update Submit

April 4, 2025

Conditions

Rhabdomyosarcoma

Keywords

rhabdomyosarcomamolecular signaturesspatial proteometargeted therapy

Outcome Measures

Primary Outcomes (1)

  • Spatial Proteomic Profiling of Tumor Samples

    Evaluate the ability to obtain distinct proteomic profiles from at least 75% of tumor samples analyzed, with a minimum of two distinct profiles identified per sample.

    12 months (study duration)

Interventions

None AHTOTHER

This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.

Eligibility Criteria

Age0 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Oscar Lambret Center (Lille, France)

You may qualify if:

  • Age between 0 and 25 years at the time of initial diagnosis
  • Diagnosis of rhabdomyosarcoma confirmed histologically
  • Care at the Oscar Lambret Center between January 2005 and November 2024
  • No objection to the re-use of data and biological samples collected as part of care for research activities.

You may not qualify if:

  • Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
  • Patient under guardianship or trusteeship.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oscar Lambret Center

Lille, Nord, 59000, France

RECRUITING

MeSH Terms

Conditions

Rhabdomyosarcoma

Condition Hierarchy (Ancestors)

MyosarcomaNeoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcoma

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2025

First Posted

April 11, 2025

Study Start

March 13, 2025

Primary Completion

December 31, 2025

Study Completion

February 28, 2026

Last Updated

April 11, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)